Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib

Por Onn, A, Tsuboi, M, Thatcher, N
Publicado em 2004

L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients

Por Portal, D, Hofstetter, L, Eshed, I, Dan-Lantsman, C, Sella, T, Urban, D, Onn, A, Bar, J, Segal, G
Publicado no Cancer Manag Res (2019)

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

Por Rodon, J., Soria, J. C., Berger, R., Batist, G., Tsimberidou, A., Bresson, C., Lee, J. J., Rubin, E., Onn, A., Schilsky, R. L., Miller, W. H., Eggermont, A. M., Mendelsohn, J., Lazar, V., Kurzrock, R.
Publicado no Ann Oncol (2015)